Elsevier

Annals of Oncology

Volume 26, Issue 12, December 2015, Pages 2375-2391
Annals of Oncology

review
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

https://doi.org/10.1093/annonc/mdv383Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer. Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety. In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types. We summarize the key adverse events reported in these studies and their management algorithms.

Key words

immune checkpoint antibody
anti-PD-1
anti-PD-L1
toxicity
adverse event

Cited by (0)